SIG
79
-2
FCX
67
14
EA
47
-3
IFF
69
13
DNB
46
-2
TSN
38
-2
DG
36
-2
PFE
37
-3
FLS
75
8
PYPL
31
2
WU
44
-2
GT
49
-3
REGN
65
2
AZO
45
2
AMGN
55
-2
BRK.B
47
2
BLK
69
11
LMT
52
2
VLO
45
6
NWL
35
-4
SIG
79
-2
FCX
67
14
EA
47
-3
IFF
69
13
DNB
46
-2
TSN
38
-2
DG
36
-2
PFE
37
-3
FLS
75
8
PYPL
31
2
WU
44
-2
GT
49
-3
REGN
65
2
AZO
45
2
AMGN
55
-2
BRK.B
47
2
BLK
69
11
LMT
52
2
VLO
45
6
NWL
35
-4
Financhill
Back

Intellia Therapeutics 10K Form

Sell
45

NTLA
Intellia Therapeutics

Last Price:
26.24
Seasonality Move:
33.25%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive NTLA News And Ratings

See the #1 stock for the next 7 days that we like better than NTLA

NTLA Financial Statistics

Sales & Book Value

Annual Sales: $36.28M
Cash Flow: $-123.17M
Price / Cash Flow: 0
Annual Sales: $10.76
Price / Book: 2.44

Profitability

EPS (TTM): -5.36000
Net Income (TTM): $-485.5M
Gross Margin: --
Return on Equity: -44.79%
Return on Assets: -37.09%

Intellia Therapeutics Earnings Forecast

Key Intellia Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,199.36% of Revenue.
  • The Net Earning history of NTLA is -1,326.51% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 1 years.

Intellia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: NTLA
CUSIP: 45826J
Website: intelliatx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 9.03
Quick Ratio: 8.45

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

NTLA Technical Analysis vs Fundamental Analysis

Sell
45
Intellia Therapeutics (NTLA) is a Sell

Is Intellia Therapeutics a Buy or a Sell?